Consensus Statement on the definition and classification of metabolic hyperferritinaemia
Luca Valenti
(1)
,
Elena Corradini
(2)
,
Leon Adams
(3)
,
Elmar Aigner
(4)
,
Saleh Alqahtani
(5)
,
Marco Arrese
(6)
,
Edouard Bardou-Jacquet
(7, 8, 9)
,
Elisabetta Bugianesi
(10)
,
Jose-Manuel Fernandez-Real
(11)
,
Domenico Girelli
(12)
,
Hannes Hagström
(13)
,
Benjamin Henninger
(14)
,
Kris Kowdley
(15)
,
Guido Ligabue
(2)
,
Donald Mcclain
(16)
,
Fabrice Lainé
(8, 9)
,
Koji Miyanishi
(17)
,
Martina Muckenthaler
(18)
,
Alessia Pagani
(19)
,
Patrizia Pedrotti
(20)
,
Antonello Pietrangelo
(2)
,
Daniele Prati
(21)
,
John Ryan
(22)
,
Laura Silvestri
(19)
,
C Wendy Spearman
(23)
,
Per Stål
(13)
,
Emmanuel Tsochatzis
(24)
,
Francesca Vinchi
(25)
,
Ming-Hua Zheng
(26)
,
Heinz Zoller
(27)
1
UNIMI -
Università degli Studi di Milano = University of Milan
2 UNIMORE - Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia
3 UWA - The University of Western Australia
4 PMU - Paracelsus Medizinische Privatuniversität = Paracelsus Medical University
5 JHU - Johns Hopkins University
6 UC - Pontificia Universidad Católica de Chile
7 NuMeCan - Nutrition, Métabolismes et Cancer
8 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
9 CIC - Centre d'Investigation Clinique [Rennes]
10 UNITO - Università degli studi di Torino = University of Turin
11 UdG - Universitat de Girona = University of Girona
12 UNIVR - Università degli studi di Verona = University of Verona
13 Karolinska University Hospital [Stockholm]
14 Leopold Franzens Universität Innsbruck - University of Innsbruck
15 WSU - Washington State University
16 Wake Forest School of Medicine [Winston-Salem]
17 Sapporo Medical University School of Medicine
18 Universität Heidelberg [Heidelberg] = Heidelberg University
19 IRCCS Ospedale San Raffaele [Milan, Italy]
20 ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia]
21 Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
22 RCSI - Royal College of Surgeons in Ireland
23 University of Cape Town
24 UCL - University College of London [London]
25 Weill Cornell Medicine [Cornell University]
26 The First Affiliated Hospital of Wenzhou Medical University [Wenzhou, China]
27 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
2 UNIMORE - Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia
3 UWA - The University of Western Australia
4 PMU - Paracelsus Medizinische Privatuniversität = Paracelsus Medical University
5 JHU - Johns Hopkins University
6 UC - Pontificia Universidad Católica de Chile
7 NuMeCan - Nutrition, Métabolismes et Cancer
8 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
9 CIC - Centre d'Investigation Clinique [Rennes]
10 UNITO - Università degli studi di Torino = University of Turin
11 UdG - Universitat de Girona = University of Girona
12 UNIVR - Università degli studi di Verona = University of Verona
13 Karolinska University Hospital [Stockholm]
14 Leopold Franzens Universität Innsbruck - University of Innsbruck
15 WSU - Washington State University
16 Wake Forest School of Medicine [Winston-Salem]
17 Sapporo Medical University School of Medicine
18 Universität Heidelberg [Heidelberg] = Heidelberg University
19 IRCCS Ospedale San Raffaele [Milan, Italy]
20 ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia]
21 Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
22 RCSI - Royal College of Surgeons in Ireland
23 University of Cape Town
24 UCL - University College of London [London]
25 Weill Cornell Medicine [Cornell University]
26 The First Affiliated Hospital of Wenzhou Medical University [Wenzhou, China]
27 IMU - Innsbruck Medical University = Medizinische Universität Innsbruck
Luca Valenti
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1235289
Connectez-vous pour contacter l'auteur
Elena Corradini
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1235290
Connectez-vous pour contacter l'auteur
Jose-Manuel Fernandez-Real
- Fonction : Auteur
- PersonId : 804153
- ORCID : 0000-0002-7442-9323
Domenico Girelli
- Fonction : Auteur
- PersonId : 1235291
- ORCID : 0000-0001-9684-1899
Guido Ligabue
- Fonction : Auteur
- PersonId : 1235292
- ORCID : 0000-0001-9304-0703
Donald Mcclain
- Fonction : Auteur
- PersonId : 1235293
- ORCID : 0000-0002-3310-2359
Koji Miyanishi
- Fonction : Auteur
- PersonId : 1235294
- ORCID : 0000-0002-6466-3458
Emmanuel Tsochatzis
- Fonction : Auteur
- PersonId : 1235295
- ORCID : 0000-0001-5069-2461
Ming-Hua Zheng
- Fonction : Auteur
- PersonId : 808086
- ORCID : 0000-0003-4984-2631
Heinz Zoller
- Fonction : Auteur
- PersonId : 1235296
- ORCID : 0000-0003-1794-422X
Résumé
Hyperferritinaemia is a common laboratory finding that is often associated with metabolic dysfunction and fatty liver. Metabolic hyperferritinaemia reflects alterations in iron metabolism that facilitate iron accumulation in the body and is associated with an increased risk of cardiometabolic and liver diseases. Genetic variants that modulate iron homeostasis and tissue levels of iron are the main determinants of serum levels of ferritin in individuals with metabolic dysfunction, raising the hypothesis that iron accumulation might be implicated in the pathogenesis of insulin resistance and the related organ damage. However, validated criteria for the non-invasive diagnosis of metabolic hyperferritinaemia and the staging of iron overload are still lacking, and there is no clear evidence of a benefit for iron depletion therapy. Here, we provide an overview of the literature on the relationship between hyperferritinaemia and iron accumulation in individuals with metabolic dysfunction, and on the associated clinical outcomes. We propose an updated definition and a provisional staging system for metabolic hyperferritinaemia, which has been agreed on by a multidisciplinary global panel of expert researchers. The goal is to foster studies into the epidemiology, genetics, pathophysiology, clinical relevance and treatment of metabolic hyperferritinaemia, for which we provide suggestions on the main unmet needs, optimal design and clinically relevant outcomes.